Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care Infusion Site Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedFidelis CarePolicy CP.PHAR.493

    Infusion Therapy Site of Care Optimization

    Customize your policy alerts

    Sign up for Fidelis Care Policy CP.PHAR.493 alerts

    Get alerted when Policy CP.PHAR.493 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the medically necessary site of care for intravenous and injectable specialty infusion services, including outpatient hospital, non-hospital outpatient, ambulatory infusion, physician-office, pharmacy, and home infusion administration for Fidelis Care members.

    Policy Summary
    PayerFidelis Care
    PolicyInfusion Therapy Site of Care Optimization
    Policy CodePolicy CP.PHAR.493
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with documentation that the requested site of care meets all criteria and includes a qualifying exception.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The policy was reinstated with updated business-line and market applicability, reasons a specialty pharmacy may be unable to provide a requested drug at an alternative infusion site, and an appendix of applicable drugs.

    The policy was updated to include Indiana, New Hampshire, and Ohio markets effective 4/1/2026.

    The policy was updated to include the Tennessee Exchange and New York Essential lines of business.

    The policy was reinstated with updated applicability, including removal of Commercial and other lines of business and specification of applicable HIM states.

    The policy added reasons a specialty pharmacy may be unable to provide a requested drug for an alternative infusion site and added an appendix identifying applicable drugs.

    The policy updated market applicability to include Indiana, New Hampshire, and Ohio.

    The policy updated applicability to include Tennessee Exchange and New York Essential lines of business.

    Least intensiveSite-of-care standard
    Up to 1 yearMaximum approval duration
    Not permittedRe-authorization
    19, 22Hospital outpatient POS
    12, 24, 11, 01Alternative-setting POS
    4/1/2026New market inclusion date

    Coverage Criteria

    Initial approval criteria

    Requests for outpatient hospital or non-hospital outpatient infusion must meet all of the following:

    Initial outpatient infusion site-of-care criteria

    • Basic site-of-care requirements

      • The requested drug is listed on the Alternative Site of Care List.
      • No home infusion provider is available.
      • No lower-cost site of care is available to provide administration.
      • The specialty pharmacy does not have access to the drug for delivery to the requested outpatient hospital or non-hospital outpatient infusion center.
    • ONE qualifying exception

      • Initial dose or restart: The request is for the first administration or a restart after at least 6 months, is for a short duration such as 4 weeks, and includes a documented transition plan to home infusion or an ambulatory infusion service.Restart after ≥ 6 months; short duration such as 4 weeks
      • FDA labeling: FDA-approved drug labeling explicitly requires outpatient hospital administration.
      • Severe or life-threatening adverse effects: Medical records document a qualifying severe or life-threatening adverse effect, including but not limited to seizures, anaphylaxis with no alternatives, myocardial infarction, or renal complications.

        See Appendix C in the policy.

      • Unsafe alternative setting: Medical records document that home infusion or an ambulatory infusion service is unsafe because of a medical or behavioral impairment, such as severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate intravenous fluids, or cognitive impairment affecting safety.

    Continued approval

    Continued approval is not available through re-authorization under this policy.

    Continued site-of-care review: Re-authorization is not permitted. For reassessment of the requested site of care, the member must meet the initial approval criteria and the provider must submit updated medical records or infusion records documenting the member's current site-of-care needs and the need for monitoring and advanced treatment capabilities beyond those routinely needed for the infusion therapy.

    Approval duration is not applicable because re-authorization is not permitted.

    Qualifying site-of-care exception

    Coverage of a site-of-care exception requires documented medical necessity and patient-safety risk.

    ONE qualifying site-of-care exception

    • Severe or life-threatening adverse effect: The patient has a documented history of a qualifying severe or life-threatening adverse effect, including but not limited to seizures, anaphylaxis with no alternatives, myocardial infarction, or renal complications.
    • Medical or behavioral impairment: Home or alternative-site infusion is unsafe because of a documented medical or behavioral impairment.

      The safety risk must be documented in chart notes. Examples include severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate intravenous fluids, or cognitive impairment affecting safety.

    Hospital outpatient or non-hospital outpatient administration is not covered when a preferred site of care is available, including a home infusion provider or lower-cost site capable of providing administration.

    The following are not qualifying reasons for a site-of-care exception: trypanophobia or fear of needles, pediatric status, patient preference or convenience, frequent laboratory monitoring, or continuation of services from a previous plan.

    Home or alternative-site infusion is not medically necessary solely because of trypanophobia, pediatric status, convenience or preference, frequent laboratory monitoring, or continuation of services from a previous plan.

    Applicable Codes and Approval Durations

    Restart interval
    Restart intervalAt least 6 months (≥ 6 months)
    When it appliesThe request must be for the first administration or a restart after at least 6 months.
    Related requirementThe restart request must be for a short duration, such as 4 weeks, with a documented transition plan to home infusion or an ambulatory infusion service.
    Short-duration initial or restart approval
    Short-duration approvalA short duration, such as 4 weeks, may apply to an initial dose or restart request.
    Applicable requests

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Site-of-Care Authorization

    Obtain prior authorization for requested outpatient hospital or non-hospital outpatient infusion. The request must establish that the drug is on the Alternative Site of Care List, no home infusion provider or lower-cost administration site is available, and a specialty pharmacy cannot deliver the drug to the requested infusion setting.

    • The injectable medication must separately meet applicable medical-necessity criteria for coverage.
    • Submit documentation supporting all applicable approval criteria.
    Prior Authorization

    Site-of-Care Exception Authorization

    Obtain authorization for a home or alternative-site exception when the record supports that the preferred site is unsafe or otherwise qualifies for an exception. Chart documentation must describe the applicable medical or behavioral impairment and the related patient-safety concern.

    • Qualifying circumstances may include severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, or cognitive impairment affecting safety.

    Policy Background

    Specialty infusion therapy involves intravenous or injectable administration of medications used to manage complex and often chronic conditions. Administration should occur in the least intensive setting appropriate for safe delivery, considering home infusion, non-hospital outpatient infusion, physician offices, ambulatory infusion centers, and pharmacies before hospital outpatient administration. The policy may also consider the cost-effectiveness of alternative services, settings, or supplies.

    Key Definitions

    Site of Care
    Site of CareRedirection of administration and/or dispensing of specialty drugs from outpatient facilities to another appropriate setting.
    Outpatient facilitiesExamples include hospitals and community offices.
    Alternative settingsExamples include a home-based setting, ambulatory surgical or infusion center, or pharmacy.
    Specialty infusion therapy
    Specialty infusion therapyIntravenous or injectable administration of medication.
    Clinical purposeMedication administration that helps members manage complex and often chronic conditions.
    Administration routes

    Initial Therapy

    Initial therapy

    Initial therapy requires all basic site-of-care requirements plus one qualifying exception.

    Initial therapy site-of-care request

    • Basic site-of-care requirements

      • The requested drug is listed on the Alternative Site of Care List.
      • No home infusion provider is available.
      • No lower-cost site of care is available to provide administration.
      • The specialty pharmacy does not have access to deliver the drug to the requested infusion center.
    • ONE qualifying exception

    Continuation and Maintenance Therapy

    Continued approval

    Re-authorization is not permitted.

    Continued therapy: Members must meet the initial approval criteria. The provider must submit updated medical or infusion records supporting continued need for monitoring and advanced treatment capabilities beyond what is routinely needed for the infusion therapy.

    Approval duration is not applicable because re-authorization is not permitted.

    Maintenance therapy only

    The following products are restricted to maintenance therapy only.

    Maintenance therapy: Pembrolizumab (Keytruda) and nivolumab (Opdivo) are listed for maintenance therapy only.

    Site-of-Care Requirements

    Note

    Use the least intensive appropriate setting

    Render infusion services in the least intensive setting appropriate for delivery. Consider home infusion, non-hospital-affiliated outpatient infusion, ambulatory infusion centers, physician offices, and pharmacies before requesting a more intensive setting.

    Note

    Consider office administration

    Use a physician office or other non-hospital-affiliated outpatient setting when it is the least intensive setting appropriate for safe delivery and no qualifying requirement supports a more intensive setting.

    Note

    Consider an infusion center

    Use an ambulatory or other non-hospital-affiliated infusion center when it is the least intensive setting appropriate for delivery. A more intensive setting requires the applicable approval criteria and a qualifying exception.

    Biosimilar Applicability

    Billing Rule

    J1745 includes infliximab biosimilars

    The Alternative Site of Care List entry for HCPCS J1745 (infliximab; Remicade) includes all biosimilars.

    • J1745 — infliximab; Remicade/infliximab; includes all biosimilars.
    Billing Rule

    J1786 includes imiglucerase biosimilars

    The Alternative Site of Care List entry for HCPCS J1786 (imiglucerase; Cerezyme) includes all biosimilars.

    • J1786 — imiglucerase; Cerezyme; includes all biosimilars.
    Billing Rule
    Policy Summary
    PayerFidelis Care
    PolicyInfusion Therapy Site of Care Optimization
    Policy CodePolicy CP.PHAR.493
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with documentation that the requested site of care meets all criteria and includes a qualifying exception.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Approval DurationsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial TherapyContinuation and Maintenance TherapySite-of-Care RequirementsBiosimilar Applicability
    The request must be for the first administration or a restart after at least 6 months.
    Transition planThe provider must submit a documented transition plan to home infusion or an ambulatory infusion service.
    Documentation Required

    Clinical Documentation Required

    Submit office chart notes, laboratory results, or other clinical information supporting that the member meets all approval criteria for the requested site of care and medication.

    Documentation Required

    Exception Documentation

    For an initial dose or restart exception, submit records showing that the request is for the first administration or a restart after at least 6 months, is short duration (for example, 4 weeks), and includes a documented transition plan to home infusion or an ambulatory infusion site. Also submit records supporting any qualifying FDA-label, adverse-effect, or safety exception.

    • FDA-approved labeling may explicitly require outpatient hospital administration.
    • Qualifying adverse effects may include seizures, anaphylaxis with no alternatives, myocardial infarction, or renal complications.
    Documentation Required

    Updated Records for Continued Need

    For continued approval review, submit current medical records or infusion records demonstrating the ongoing need for monitoring and advanced treatment capabilities beyond those routinely required for the infusion therapy.

    Documentation Required

    Document Medical Necessity

    Document the medical necessity for outpatient hospital or other higher-intensity administration when applicable. The record must identify a qualifying severe or life-threatening adverse effect or another specific qualifying circumstance supporting the requested site.

    • Examples include seizures, anaphylaxis with no alternatives, myocardial infarction, and renal complications.
    Documentation Required

    Document Patient-Safety Risk

    Document in the chart why home infusion or ambulatory infusion site care is unsafe because of a medical or behavioral impairment. Include the specific condition, the resulting safety concern, and why the requested setting is needed.

    • Examples include severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, and cognitive impairment affecting safety.
    Denial Risk

    Alternative Site Available or Exception Unsupported

    Requests may be denied when a preferred, less intensive site of care is available or when the submitted exception documentation does not support the requested setting. The plan may compare the cost-effectiveness of alternative services, settings, or supplies.

    • Alternative sites may include a non-hospital-affiliated outpatient infusion center, physician office, or home infusion.
    Denial Risk

    Preferred Site of Care Available

    Hospital outpatient or non-hospital outpatient administration is not covered when a preferred site of care is available, including an available home infusion provider or lower-cost site capable of administering the drug.

    Denial Risk

    Re-authorization Not Permitted

    Re-authorization is not permitted under this policy. At reassessment, the member must meet the initial approval criteria, and updated medical or infusion records must be submitted.

    • Approval duration is up to one year or the length of the drug approval; continued approval duration is not applicable.
    Denial Risk

    Non-Qualifying Site-of-Care Rationale

    Site-of-care requests are not supported by non-qualifying reasons such as needle fear, pediatric age, preference or convenience, frequent laboratory monitoring, or continuation of services from a previous plan.

    • These circumstances do not establish the required medical necessity or patient-safety exception.
    Denial Risk

    Insufficient Safety Documentation

    A request may be denied when chart documentation does not establish that home or ambulatory infusion site care is unsafe. General assertions without a specific medical or behavioral impairment and related safety risk are insufficient.

    • Document the relevant clinical facts, such as access limitations, caregiver absence, cardiopulmonary disease, fluid intolerance, or cognitive impairment affecting safety.
    Therapy may be administered intravenously or by injection.
    FDA
    FDAFood and Drug Administration.
    Policy useFDA-approved drug labeling is one qualifying exception when it explicitly requires outpatient hospital administration.
    Documentation contextThe provider must submit medical-record documentation supporting the applicable FDA-labeling exception.
    IV
    IVIntravenous.
    Policy useIV refers to administration into a vein, including IV fluids referenced in the safety criteria.
    Related therapySpecialty infusion therapy may involve intravenous or injectable medication administration.
    • Initial dose or restart: The request is for the first administration or a restart after at least 6 months, is for a short duration such as 4 weeks, and includes a documented transition plan to home infusion or an ambulatory infusion service.Restart after ≥ 6 months; short duration such as 4 weeks
    • FDA labeling: FDA-approved drug labeling explicitly requires outpatient hospital administration.
    • Severe or life-threatening adverse effects: Medical records document a qualifying severe or life-threatening adverse effect, including but not limited to seizures, anaphylaxis with no alternatives, myocardial infarction, or renal complications.
    • Unsafe alternative setting: Medical records document that home infusion or an ambulatory infusion service is unsafe because of a medical or behavioral impairment, such as severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate intravenous fluids, or cognitive impairment affecting safety.
    Prior Authorization

    Justify hospital outpatient administration

    Outpatient hospital administration is permitted only when the drug is on the Alternative Site of Care List, no preferred home or lower-cost site is available, the specialty pharmacy lacks access to deliver the drug to the requested infusion center, and a qualifying exception is documented.

    Documentation Required

    Support home infusion eligibility

    Home or alternative-site infusion is appropriate only when chart documentation supports that facility-based care is not required and the patient’s safety risk is adequately addressed.

    Note

    Use facility-based care when home is unsafe

    Use a facility-based infusion setting when home or alternative-site administration is unsafe because of a medical or behavioral impairment, including severe venous-access issues without a vein finder, absence of a caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, or cognitive impairment affecting safety.

    Rituxan and rituximab biosimilars are listed

    The applicable-drug list includes Rituxan and rituximab biosimilar products.

    • J9312 — rituximab; Rituxan.
    • Q5115 — Truxima; Q5119 — Ruxience; Q5123 — Riabni.